Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
O'Leary
Michael P
MP
D001559:Benzhydryl Compounds / Q000627:therapeutic use*; D003408:Cresols / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018727:Muscarinic Antagonists / Q000627:therapeutic use*; D010665:Phenylpropanolamine / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D000068737:Tolterodine Tartrate; D016896:Treatment Outcome; D014555:Urination Disorders / Q000209:etiology / Q000503:physiopathology / Q000517:prevention & control*; D014563:Urodynamics / Q000187:drug effects
D001559:Benzhydryl Compounds; D003408:Cresols; D018727:Muscarinic Antagonists; D010665:Phenylpropanolamine; D000068737:Tolterodine Tartrate